Inefficient T-cell homing to tissues limits adoptive T-cell immunotherapy of solid tumors. aLb2 and a4b1 integrins mediate trafficking of T cells into tissues via engagement of ICAM-1 and VCAM-1, respectively. Inhibiting protein kinase A (PKA)-mediated phosphorylation of a4 integrin in cells results in an increase in aLb2-mediated migration on mixed ICAM-1-VCAM-1 substrates in vitro, a phenomenon termed "integrin trans-regulation." Here, we created an a4(S988A)-bearing mouse, which precludes PKA-mediated a4 phosphorylation, to examine the effect of integrin trans-regulation in vivo. The a4(S988A) mouse exhibited a dramatic and selective increase in migration of lymphocytes, but not myeloid cells, to sites of inflammation. Importantly, we found that the a4(S988A) mice exhibited a marked increase in T-cell entry into and reduced growth of B16 melanomas, consistent with antitumor roles of infiltrating T cells and progrowth functions of tumor-associated macrophages. Thus, increased a4 trans-regulation of aLb2 integrin function biases leukocyte emigration toward lymphocytes relative to myeloid cells and enhances tumor immunity.
Introduction
Different classes of leukocytes have opposing effects on the growth of tumors. Lymphocytes, particularly T cells, are critical components of the host defense that limit tumorigenesis (1) . In sharp contrast, myeloid cells contribute cytokines that promote both tumor growth and angiogenesis (2, 3) . a4 integrins play an important role in lymphocyte entry into sites of tissue injury (4, 5) in part because they markedly potentiate cell migration via signaling mediated by binding of paxillin to the a4 cytoplasmic tail (6) . Protein kinase A (PKA)-mediated phosphorylation of the a4 integrin tail at Ser 988 inhibits paxillin binding in migrating cells (7) ; consequently, the a4(S988A) mutation stabilizes the a4-paxillin interaction and increases a4 integrin signaling. The increased signaling downstream of a4(S988A) enhances integrin a L b2(LFA-1)-mediated migration of cells, a phenomenon termed integrin trans-regulation (8) .
Here, we examined the biologic consequences of blockade of a4 phosphorylation by generating a4(S988A) mutant mice and found that these mice manifest a dramatic increase in recruitment of lymphocytes, but not myeloid cells, to an inflammatory site. We found that the a4(S988A) mutation markedly increased the abundance of T cells, but not myeloid cells, in heterotopic B16 melanomas. Increased lymphocyte homing is needed for efforts to develop adoptive immunotherapies for solid tumors (9) (10) (11) (12) (13) (14) .
The potential therapeutic value of this form of integrin transregulation was established by the finding that subcutaneously implanted melanomas grew more slowly in a4(S988A) mice associated with markedly enhanced recruitment of T cells, but not myeloid cells, to the tumors. Thus, increasing integrin transregulation by blocking a4 integrin phosphorylation selectively recruits lymphocytes, but not myeloid cells, thereby reducing tumor growth. This finding suggests that modulation of integrin trans-regulation may be useful in overcoming a limitation of adoptive cellular immunotherapy of solid tumors.
Materials and Methods
Mice a4(S988A) mice were generated as described in Supplementary Material of ref. 16 . These mice were bred to create homozygous germline knock-ins and backcrossed to BL6 for >8 generations for all experiments, unless otherwise noted. For assessment of T-cell cytotoxic function, a4(S988A) mice were crossed with the OT-1 strain. Rag1 À/À mice were used as recipients for in vivo competitive migration experiments. All mice were housed at the University of California San Diego animal facility, and all experiments were approved by the Institutional Animal Care and Use Committee.
Cytospin4 instrument (ThermoShandon) and stained with DiffQuick to differentiate cell types by light microscopy. The percentages of T, B1, and B2 cells were assessed by flow cytometry using fluorochrome-conjugated anti-CD3, anti-B220, and anti-Mac-1 antibodies. For competitive peritonitis assay, peritonitis was elicited as described above, but in Rag1 À/À mice. Twenty-four hours after thioglycollate injection, mice received an i.v. injection of a mixture of splenocytes from adult a4(S988A) or control Ly5.1 a4(wt). Splenocyte suspensions and peritoneal lavages were stained using antibodies against CD3, CD8, and Ly5.1. The ratio of a4(S988A) to Ly5.1 þ a4(wt) splenocytes was compared between spleen and peritoneum as a measure of enrichment for a4(S988A) cells in the inflammatory site.
Lymphoid compartments
Bone marrow cell suspensions were prepared by flushing femur and tibia bones from adult a4(S988A) and a4(wt) mice. Singlecell suspensions from bone marrow, spleen, and thymus were treated with ACK lysis buffer, counted, and stained with fluorochrome-conjugated antibodies (eBioscience) against mouse B220 (RA3-6B2), IgM (II/41), IgD (11-26c), CD21/35 (7G6), CD23 (B3B4), CD3 (145-2C11), CD4 (GK1.5), CD8 (53-6.7) at optimized concentrations. Cells were washed and analyzed by flow cytometry. For integrin expression analysis, blood was collected by tail bleed, treated with ACK lysis buffer, and stained with anti-CD3, anti-a4, anti-aLb2 integrin, or isotype control fluorochrome-conjugated antibodies before flow cytometry.
Humoral immune response
For antigen-specific antibody responses, a4(S988A) and a4(wt) mice (F5 backcross to BL6) were injected i.p. with 100 mg trinitrophenol-keyhole limpet hemocyanin (TNP-KLH; Biosearch) emulsified in 250 mL complete Freund's adjuvant (T-cell-dependent antigen). Blood serum was collected by centrifugation of tail vein bleed (100-200 mL with 1-2 mmol/L EDTA solution as an anticoagulant) before (preimmune) and at 1, 2, and 3 weeks after immunization. TNPspecific antibody concentrations in blood sera were assessed by direct ELISA with trinitrophenol-ovalbumin (TNP-OVA) as the coating antigen and alkaline phosphatase-conjugated polyclonal anti-mouse IgG (Sigma) as the detection antibody.
Migration assay
Resting B or T cells were purified from spleens of adult a4 (S988A) and control a4(wt) mice by negative depletion. Macrophages were differentiated from a4(S988A) or control a4(wt) bone marrow by culture in 30% L292 supernatant for one week. In vitro migration was assessed following a modified Boyden Chamber assay (8) . Briefly, transwells (Costar) with 3.0-mm polycarbonate membrane inserts were coated with VCAM-1 and/or ICAM-1 Fc fusion proteins in carbonate buffer, pH 8.0. Transwell membranes were blocked in PBS, 2% BSA 30 minutes at room temperature. Cells (2.0 Â 10 5 ) were added to the top chamber in complete medium (10% FBS). Complete medium containing 15 ng/mL stromal-derived factor-1a (SDF-1a; R&D Systems) was added to the lower chamber. To observe macrophage migration, 20 ng/mL of both SDF-1 and MCP-1 was necessary. After a 4-hour incubation at 37 C (overnight for macrophages), cells in the lower chamber and underside of transwell were harvested and counted by hemacytometer.
B16 melanoma model
B16 (f1 subclone) or Lewis lung carcinoma (LLC) cells were expanded in culture in complete medium (DMEM supplemented with 10% FBS, L-glutamine, bME, and pen/strep antibiotics). B16 cells (3 Â 10 5 ) or LLC cells (1 Â 10 6 ) were injected s.c. into the right hind flanks of adult a4(S988A) or control a4(wt) mice. When tumors became visible, length and width were measured daily with calipers. Tumors were assumed to be ellipsoid, and volume was calculated using the formula: (length Â width 2 )/2. Mice were sacrificed on day 15, and tumors were excised and weighed. To analyze tumor-infiltrating leukocytes (TIL), tumors were digested with collagenase (Sigma) for 20 to 30 minutes at 37 C and further processed to a single-cell suspension using a 7-mL tissue grinder (Kontes) and counted. Fluorochrome-conjugated antibodies were used to stain for tumor-infiltrating CD45 antibody (53-6.7, 100 mg) or a combination of anti-CD4, anti-CD8, and anti-NK1.1 antibodies (150 mg each), compared with isotype control antibody i.p. 2 days before and 5 days after B16 tumor-cell inoculation. Splenocytes harvested on day 15 were stained with antibodies specific for CD3, CD4, and CD8 to determine efficiency of T-cell depletion.
Analysis of clonal expansion in vivo
To analyze clonal expansion on a polyclonal T-cell receptor (TCR) background, a4(S988A) and wt mice were immunized with a combination of 100 mg poly I:C (Invivogen), 50 mg anti-CD40 antibody (Biolegend), and 500 mg ovalbumin protein (Sigma) in PBS i.p. Six days later, mice were sacrificed and spleen cells were stained using anti-CD8 þ antibody and an H-2K b -SIINFEKL(PE) tetramer (Coulter).
Assessment of CD8 T-cell cytotoxic function
To generate functional CTLs, splenocytes from a4(S988A) and wt-OT-1 mice were cultured with 1 mg/mL SIINFEKL and 100 U/mL IL2 (NCI) for 6 days. Degranulation as a measure of cytotoxicity was measured as exposure of CD107a (LAMP-1) on the outer cell membrane. On day 6 following SIINFEKL stimulation, CTLs were harvested, counted, and cultured with SIINFEKL-pulsed (1 mg/mL for 1-2 hours) or -unpulsed splenocytes as targets in the presence of anti-LAMP-1-PE antibodies (eBioscience) for 2.5 hours at 37 C. Effector:target cultures were stained with anti-CD8 antibodies and analyzed by flow cytometry. For target lysis in vitro, CTLs were generated as above and cultured with an approximately 50/50 mixture of peptidepulsed (CFSElo) and -unpulsed (CFSEhi) splenocyte targets overnight. Specific lysis is the percentage decrease in the percentage of the peptide-pulsed peak between CTL-containing and no-CTL control cultures.
Statistical analysis
The two-tailed t test was used for statistical comparison between groups in all experiments, except where otherwise noted. A value of P < 0.05 was considered statistically significant.
Results and Discussion
The a4(S988A) mutation selectively increases lymphocyte migration to an inflammatory site
We used homologous recombination to generate a4(S988A) mice ( Supplementary Fig. S1 ) and compared them to wt C57BL/6 mice as controls. We observed no statistically significant differences in formed elements of the blood (Supplementary Fig. S2A ) or in lymphocyte numbers (with the possible exception of increased Pro-B cells in the bone marrow) in primary or secondary lymphoid tissue ( Supplementary Fig. S2B ) in a4(S988A) mice. Humoral immune responses to a T-dependent antigen were also similar between a4(S988A) and wt mice ( Supplementary  Fig. S2C ).
Because the a4(S988A) mutation inhibits migration on substrates containing purified a4 integrin ligands (7), we hypothesized that a4(S988A) mice might exhibit a similar defect in leukocyte migration in vivo. We therefore used a thioglycollateinduced peritonitis model to test the effect of this mutation on leukocyte entry into an inflammatory site. To our great surprise, we observed a sharp increase in the number of lymphocytes infiltrating the peritoneum (Fig. 1) , whereas myeloid cell infiltration was unaffected. We stained the peritoneal lavage with antibodies to identify B1, B2, and T lymphocytes and found that both B2 and T cells exhibited significantly (>3-4-fold) greater numbers in the a4(S988A) mice compared with that in the controls (Fig. 1) . In contrast, the numbers of B1 cells, a resident peritoneal population (15) , showed no statistically significant differences from controls, indicating that the a4(S988A) mutation specifically affects influx of lymphocytes. An in vivo competitive migration assay ( Supplementary Fig. S3 ) using a mix of wt (congenically marked) and a4(S988A) splenocytes confirmed that the increased migration of a4(S988A) T cells is intrinsic to leukocytes and not merely due to effects of a4 phosphorylation in endothelial cells (16) or other changes in the inflammatory environment (e.g., production of chemokines by resident cells) in these mice. Therefore, interfering with a4 integrin phosphorylation selectively increased homing of lymphocytes to a site of inflammation but had no obvious effect on myeloid cells.
Integrin trans-regulation explains increased migration of a4(S988A) lymphocytes Our initial expectation that the a4(S988A) mutation would decrease homing was based on results from in vitro migration on purified a4 integrin ligands. In vivo migration to an inflammatory site is complex and involves several classes of integrins (17) . We previously reported that the presence of small amounts of a4 integrin ligands (e.g., VCAM-1) increases the migration of Jurkat T cells on aLb2 integrin substrates (e.g., ICAM-1) in vitro (8) . Paxillin binding to a4 is required for this effect, and enforced paxillin-a4 association enhanced the trans-regulation of aLb2 by a4 integrins through increasing the activation of FAK and Pyk2 kinases (8, 18) . The a4(S988A) mutation that blocks PKA phosphorylation of the a4 cytoplasmic tail could therefore enhance aLb2-dependent migration. The in vivo peritonitis experiment requires migration on mixed substrates and is dependent on both a4 and b2 integrins (17) , conditions in which the a4(S988A) mutation could increase migration of lymphocytes (8) . To explore this possibility in a controlled setting, we purified B and T cells from a4(S988A) mice and measured their ability to migrate in vitro on purified a4 ligand (VCAM-1), purified b2 ligand (ICAM-1), or mixed substrates (VCAM-1 þ ICAM-1) in response to the chemokine SDF-1a. Using a modified Boyden chamber assay, we confirmed that a4(S988A) lymphocytes exhibited reduced migration on a purified a4 integrin ligand: VCAM-1 ( Fig.  2A) . In contrast, when plated on substrates containing predominantly ICAM-1 and small amounts of VCAM-1, both B and T cells from a4(S988A) mice displayed enhanced migration that was dependent on both a4 and b2 integrins ( Fig. 2B; Supplementary  Fig. S4 ). This observation cannot be explained by differences in surface integrin expression levels, as T cells from a4(S988A) and a4(wt) mice show no difference in staining for a4 or aLb2 integrins (Fig. 2C ). These data indicate that the a4(S988A) mutation provides an increase in b2 integrin-dependent migration, i.e., integrin trans-regulation in primary lymphocytes.
Increased integrin trans-regulation reduces tumor growth by increasing T-cell homing
Specifically increasing lymphocyte entry into an inflammatory site might offer therapeutic benefit during an immune response to a tumor. T-cell migration to solid tumors is important for tumor immunity (1), whereas tumor infiltration by macrophages may promote tumor growth through increased angiogenesis and suppressed immunity (2, 3) . In adoptive immunotherapy (11) (12) (13) (14) 19) , na€ ve T cells are modified and activated in vitro; however, T-cell homing is a critical limiting variable in solid tumor adoptive immunotherapy (9, 10) . Based on our results with the peritonitis model, we hypothesized that a4(S988A) mice may have increased ability to resist tumors due to selective migration of lymphocytes to the tumor site. We tested this idea using a melanoma model (20) , in which B16 melanoma cells are injected s.c., and tumor size is measured by weighing excised tumors 15 days later. a4 (S988A) mice had approximately 5-fold smaller tumors than wt BL6 controls (Fig. 3A) , indicating that blocking a4 integrin phosphorylation on Ser988 increased tumor protection. This observation was not unique to the B16 melanoma, as a4 (S988A) mice also displayed increased resistance to the growth of Lewis lung carcinoma (Supplementary Fig. S5 ).
We next asked whether the a4(S988A) resistance to tumors was associated with increased T-cell homing. Indeed, B16 tumors in a4(S988A) mice had greater concentrations of T cells than those grown in wt mice (Fig. 3B, left) . This finding was in striking contrast with a similar number of macrophages found in tumors from mice of both genotypes, supporting the idea that the decreased tumor growth is a result of selective homing of lymphocytes versus macrophages in the a4(S988A) mice. Among Increased integrin trans-regulation in a4(S988A) lymphocytes. B and T cells were purified from spleens of a4(S988A) or control a4(wt) mice. Chemotactic migration toward SDF-1a (15 ng/mL) was assessed using a modified Boyden Chamber assay in wells coated with (A) VCAM-1 alone (2 mg/mL) or (B) ICAM-1 (5 mg/mL) AE VCAM-1 (0.02 mg/mL). For anti-integrin antibody-blocking studies, cells were treated with 10 mg/mL of either anti-a4 or anti-b2 integrin before the assay. B, percentage of increase in migration on ICAM-1 þ VCAM-1 compared with ICAM-1 alone 100
Error bars, SEM of 4 mice for each group. C, surface integrin expression levels on circulating a4(S988A) T cells. Blood leukocytes from a4(S988A) and a4(wt) control adult C57BL/6 mice (n ¼ 3 per group) were stained with antibodies specific for T cells (CD3), a4 integrins (CD49d), and aLb2 integrin heterodimer and analyzed by flow cytometry. Representative histograms show a4 or aLb2 staining (soild and dotted lines) compared with nonspecific isotype control staining (filled peak). Bar graphs summarize staining from 3 mice per group; no statistically significant differences were observed. D MFI, change in mean fluorescence intensity.
lymphoid cells, tumors in a4(S988A) mice had significantly greater numbers of CD4 þ , CD8 þ , and regulatory T cells; NK-cell abundance showed a modest, but statistically insignificant, increase compared with that of controls (Fig. 3B, right) . The increased density of tumor-infiltrating T cells seen in a4(S988A) mice could be due to subtle, unrelated immunologic changes in this strain such as greater clonal expansion of tumor-specific T cells; however, expansion of antigen-specific T cells (SIINFEKL-tetramer þ ) was similar between a4(S988A) and a4(wt) mice in response to immunization with ovalbumin (Fig. 3C) . Furthermore, the cytotoxic function of a4(S988A) CD8 þ T cells was nearly identical to that of wt (Fig. 3D ) cells as measured by degranulation of a4(S988A) OT-1 CD8 þ T cells and specific lysis of SIINFEKL-pulsed target cells. Thus, we concluded that the reduction in tumor growth observed in a4(S988A) mice is largely ascribable to increased lymphoid-cell homing. As an additional test of this conclusion, we used antibodies to deplete the majority of CD4 T, CD8 T, and NK cells. Depleting these multiple lymphoid subsets reversed the reduction in tumor growth in a4(S988A) relative to wt mice ( Supplementary Fig. S6A ). In contrast, partial depletion of CD8 T cells did not abolish the reduced tumor growth in a4(S988A) mice ( Supplementary  Fig. S6B ). Thus, the capacity of the a4(S988A) mutation to increase the recruitment of multiple lymphocyte subsets is responsible for its ability to enhance tumor resistance. The differential requirement of b2 integrins for migration of lymphocytes or myeloid cells in vivo can account for the remarkable leukocyte specificity of this form of trans-regulation. Whereas aLb2 plays a major primary role in the migration of T cells to inflammatory sites (17, (21) (22) (23) , macrophage migration to 
Treg, and NK1.1 þ NK cells. Error bars, SEM of !10 mice per group. Ã , P < 0.015; ÃÃ , P < 0.002. C, T-cell clonal expansion. a4(S988A) and a4(wt) control littermate mice were immunized with ovalbumin protein, anti-CD40, and Poly I:C, i.p. in PBS. Six days later, splenocytes were isolated and stained with anti-CD8 antibody and an H-2K b -SIINFEKL tetramer. D, T-cell cytotoxic function. Splenocytes of 8-to 12-week-old OT-I þ a4(S988A)
or OT-1 þ a4(wt) control littermate mice were differentiated to CTLs in vitro with SIINFEKL (1 mg/mL) and IL2 for 5 days and cultured for 2 hours at the indicated effector-to-target ratios (E:T) in the presence of anti-LAMP-1 antibody, followed by staining for CD8 and flow cytometric analysis. For target lysis, CTLs were cultured with SIINFEKL-pulsed or -unpulsed targets that had been differentially labeled with carboxyfluorescein diacetate succinimidyl ester. Specific killing was detected by flow cytometry as the decrease in the percentage of specific targets. No statistically significant differences were noted, with the exception of the 9:1 E:T ratio, at which the a4(S988A)-specific killing was 3.7% lower than that for a4(wt) CTLs (P < 0.005). n ¼ 3 mice per group. Experiment was performed twice.
inflamed peritoneum is not dependent on b2 integrins and is reported to be solely dependent on a4b1 (24, 25) . Thus, trans-regulation of migration would be absent in monocytes and macrophages because b2 integrins are not utilized. Indeed, we did not observe increased migration of macrophages from a4(S988A) or a4(wt) mice ( Supplementary Fig. S7 ) on mixed ICAM-1-VCAM-1 substrates.
The finding that a4b1 trans-regulation of aLb2 integrin-mediated migration promotes tumor immunity has important therapeutic implications. Inhibiting focal adhesion kinase (FAK) can suppress such trans-regulation (8), a finding that sounds a cautionary note in the use of FAK inhibitors in tumor therapy (26) (27) (28) and suggests that the effect of these agents on lymphocyte trafficking to tumors should be evaluated. Homing of infused lymphocytes is currently a rate-limiting step in applying T-cell immunotherapy to solid tumor cancers (9) . Because lymphocytes are modified ex vivo before adoptive transfer for immunotherapy (11) (12) (13) (14) , the opportunity exists to simultaneously optimize their homing capacity by increasing integrin trans-regulation. a4 phosphorylation is type I-PKA-dependent (29) ; thus, increased transregulation could be induced by introduction of a dominant a4(S988A) integrin subunit, a cell permeating type I-specific A-kinase anchor protein (AKAP) peptide, or genetically encoded type I-specific PKA inhibitor (29, 30) . Increased integrin transregulation might also have utilities beyond tumor immunotherapy. Migration and survival of long-lived plasma cells in the bone marrow appear to be dependent on a4 and aLb2 integrins (31) (32) (33) (34) (35) and could involve integrin trans-regulation. Thus, enhanced integrin trans-regulation can offer a new approach to selectively potentiate b2 integrin-mediated homing of lymphocytes and plasma cells.
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